A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis

Trial Profile

A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Ajulemic acid (Primary)
  • Indications Systemic scleroderma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Corbus Pharmaceuticals
  • Most Recent Events

    • 07 Aug 2017 According to a Corbus Pharmaceuticals media release, extension study recently extended from 12 to 24 months' duration.
    • 07 Aug 2017 Results (n=34) published in a Corbus Pharmaceuticals Media Release.
    • 07 Aug 2017 According to a Corbus Pharmaceuticals media release, data from this trial will be presented at the 15th International Workshop on Scleroderma Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top